This page is part of the FHIR Specification (v3.5a.0: R4 Ballot 4). The current version which supercedes this version is 5.0.0. For a full list of available versions, see the Directory of published versions
. Page versions: R5 R4B R4
| Biomedical Research and Regulation Work Group | Maturity Level: N/A | Ballot Status: Informative |
Raw JSON (canonical form + also see JSON Format Specification)
Definition for Code System ResearchStudyPhase
{
"resourceType" : "CodeSystem",
"id" : "research-study-phase",
"meta" : {
"lastUpdated" : "2018-08-19T21:48:56.559+10:00"
},
"text" : {
"status" : "generated",
"div" : "<div>!-- Snipped for Brevity --></div>"
},
"extension" : [{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-wg",
"valueCode" : "brr"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-standards-status",
"valueString" : "Draft"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/structuredefinition-fmm",
"valueInteger" : 1
}],
"url" : "http://terminology.hl7.org/CodeSystem/research-study-phase",
"identifier" : [{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.4.642.1.1247"
}],
"version" : "3.5a.0",
"name" : "ResearchStudyPhase",
"title" : "ResearchStudyPhase",
"status" : "draft",
"experimental" : false,
"date" : "2018-08-19T21:48:56+10:00",
"publisher" : "HL7 (FHIR Project)",
"contact" : [{
"telecom" : [{
"system" : "url",
"value" : "http://hl7.org/fhir"
},
{
"system" : "email",
"value" : "fhir@lists.hl7.org"
}]
}],
"description" : "Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.",
"caseSensitive" : true,
"valueSet" : "http://hl7.org/fhir/ValueSet/research-study-phase",
"content" : "complete",
"concept" : [{
"code" : "n-a",
"display" : "N/A",
"definition" : "Trials without phases (for example, studies of devices or behavioral interventions)."
},
{
"code" : "early-phase-1",
"display" : "Early Phase 1",
"definition" : "Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0."
},
{
"code" : "phase-1",
"display" : "Phase 1",
"definition" : "Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients."
},
{
"code" : "phase-1-phase-2",
"display" : "Phase 1/Phase 2",
"definition" : "Trials that are a combination of phases 1 and 2."
},
{
"code" : "phase-2",
"display" : "Phase 2",
"definition" : "Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks."
},
{
"code" : "phase-2-phase-3",
"display" : "Phase 2/Phase 3",
"definition" : "Trials that are a combination of phases 2 and 3."
},
{
"code" : "phase-3",
"display" : "Phase 3",
"definition" : "Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug."
},
{
"code" : "phase-4",
"display" : "Phase 4",
"definition" : "Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use."
}]
}
Usage note: every effort has been made to ensure that the examples are correct and useful, but they are not a normative part of the specification.